An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
Eli Lilly reported that their new pill version of a diabetes drug, called Foundayo, did better than a standard treatment in a late-stage clinical trial. The company says the oral drug cut blood sugar levels more than the comparison medicine in people with type 2 diabetes. This was a Phase III study, which means the drug was tested in a larger group to see if it really works and is safe enough to be considered for approval. Foundayo is an oral form of a GLP-1 receptor agonist. That sounds technical, so here’s the simple version: GLP-1 is a natural hormone your gut releases after you eat. It tells the pancreas to release insulin (which lowers blood sugar), slows how fast your stomach empties, and helps you feel full. A “receptor agonist” is a drug that copies that hormone’s effect by switching on the same bodily switch (the receptor). Most GLP-1 drugs so far come as injections. Foundayo aims to do the same job but as a pill you can swallow. The news says the Phase III trial showed Foundayo was superior to the comparator in lowering A1C, the common lab test that measures average blood sugar over a few months. Phase III trials usually involve hundreds or thousands of participants, but the short headline doesn’t give exact numbers, how long the study ran, or details like weight change or side effects. So we should understand “superior” means the pill performed better on the main blood-sugar measure in this trial, but the report doesn’t let us judge how big the benefit was or how consistent it was across different kinds of patients. This matters because many people with type 2 diabetes prefer pills to injections. If an oral GLP-1 works well and is safe, it could make a highly effective class of diabetes medicines accessible to more patients and possibly reduce barriers to starting or staying on therapy. Doctors might have another tool for helping patients lower blood sugar, and that could reduce complications related to diabetes over time. But there are caveats. The snippet doesn’t include safety data, how common side effects were, or whether regulators have approved the drug yet. GLP-1 drugs can cause nausea, vomiting, and digestive upset, and they aren’t right for everyone — for example, people with a history of certain types of pancreatitis or specific thyroid tumors are usually advised to avoid them. Also, results in a single trial don’t guarantee the same outcome in broader real-world use. Regulators will review full data before deciding if the pill can be prescribed widely. Bottom line: Lilly’s pill version of a GLP-1 drug showed better blood-sugar lowering in a large trial, which is promising, but we need the full results and safety review before saying how big a change this will be for people with type 2 diabetes.
Source: BioSpectrum Asia